Cue Biopharma, Inc.
Here’s whether Cue Biopharma, Inc. (CUE) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+5.01% over 10 days); 3-month momentum positive (+100.7%); rising volume confirms the move (2.69x 30d avg). Concerns: RSI 71 — overbought, elevated pullback risk; weak 1-year return of -22.2%. Currently 41.1% off its 52-week high. Score: +4/7.
CUE is in a confirmed uptrend, trading above both its 50-day ($0.31) and 200-day ($0.56) moving averages. With an RSI of 71.2, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -22.2% compares to +35.1% for SPY (trailed the market by 57.3%). The current 41.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.